Veeva Systems (NYSE:VEEV) Price Target Lowered to $235.00 at Canaccord Genuity Group

Posted by Renee Jackson on Mar 5th, 2026

Veeva Systems (NYSE:VEEV – Get Free Report) had its price objective dropped by stock analysts at Canaccord Genuity Group from $280.00 to $235.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “hold” rating on the technology company’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 19.72% from the stock’s previous close.

A number of other research firms also recently weighed in on VEEV. Robert W. Baird upped their target price on Veeva Systems from $314.00 to $319.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. UBS Group upped their price objective on shares of Veeva Systems from $200.00 to $220.00 and gave the stock a “neutral” rating in a research report on Thursday. Piper Sandler decreased their target price on shares of Veeva Systems from $355.00 to $285.00 and set an “overweight” rating on the stock in a report on Thursday. Wall Street Zen cut shares of Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Royal Bank Of Canada reduced their price target on shares of Veeva Systems from $330.00 to $275.00 and set an “outperform” rating on the stock in a research report on Thursday. Eighteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Veeva Systems currently has an average rating of “Moderate Buy” and a consensus price target of $283.12.

View Our Latest Research Report on VEEV

Veeva Systems Trading Up 4.1%

VEEV stock traded up $7.81 during mid-day trading on Thursday, hitting $196.29. 5,019,755 shares of the company were exchanged, compared to its average volume of 2,261,502. Veeva Systems has a 1-year low of $168.13 and a 1-year high of $310.50. The stock has a market capitalization of $32.27 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 1.28 and a beta of 1.09. The business has a 50 day simple moving average of $204.58 and a 200-day simple moving average of $248.39.

Veeva Systems (NYSE:VEEV – Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The technology company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The business had revenue of $835.95 million for the quarter, compared to analyst estimates of $810.95 million. During the same period last year, the firm earned $1.74 earnings per share. Veeva Systems’s revenue for the quarter was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. Equities research analysts expect that Veeva Systems will post 4.35 earnings per share for the current year.

Veeva Systems declared that its board has initiated a share buyback program on Monday, January 5th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the technology company to repurchase up to 5.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total value of $231,430.00. Following the sale, the insider owned 23,204 shares in the company, valued at $5,370,101.72. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VEEV. Linden Thomas Advisory Services LLC grew its position in Veeva Systems by 0.3% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 12,444 shares of the technology company’s stock worth $3,707,000 after acquiring an additional 35 shares during the last quarter. Sigma Planning Corp boosted its stake in shares of Veeva Systems by 1.2% during the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after purchasing an additional 39 shares in the last quarter. Personal CFO Solutions LLC grew its holdings in shares of Veeva Systems by 3.5% during the third quarter. Personal CFO Solutions LLC now owns 1,163 shares of the technology company’s stock worth $346,000 after purchasing an additional 39 shares during the last quarter. AFT Forsyth & Company Inc. increased its stake in shares of Veeva Systems by 4.2% in the third quarter. AFT Forsyth & Company Inc. now owns 984 shares of the technology company’s stock valued at $293,000 after buying an additional 40 shares during the period. Finally, Williams Jones Wealth Management LLC. raised its holdings in Veeva Systems by 0.4% in the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company’s stock valued at $2,806,000 after buying an additional 40 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: Q4 beat and bullish guidance: Veeva reported $836M in revenue (up ~16%) and $2.06 EPS, topping estimates, and issued Q1 and FY‑27 guidance above consensus — a clear near‑term catalyst supporting the rally. Veeva Systems’ Stock Up After Q4 Earnings & Revenues Beat Estimates
Positive Sentiment: Subscription strength & agentic/AI momentum: subscription revenue grew ~16–17% and management highlighted “agentic” AI capabilities and CRM expansion potential that underpin longer‑term revenue diversification. Veeva Announces Fourth Quarter and Fiscal Year 2026 Results
Positive Sentiment: Longer‑term CRM opportunity: Veeva signaled CRM could reach ~10% of revenue by 2030 as AI adoption builds — supporting upside if execution continues. Veeva signals CRM to comprise 10% of revenue by 2030 as AI momentum builds
Neutral Sentiment: Mixed-but-supportive analyst reactions: several firms cut price targets but kept buy/overweight ratings (e.g., TD Cowen, Piper, Needham cuts), while others raised or kept targets (Stifel, Truist reaffirmation, Morgan Stanley). The net effect is continued analyst interest but varied valuation views. Veeva Systems Analyst Says AI Push Keeps Stock Attractive
Negative Sentiment: Analysts trimmed forecasts/targets: several shops cut models and targets after the print, signaling concerns about decelerating growth and margin pressure despite the beat — a potential headwind for sentiment if future quarters slow. These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results
Negative Sentiment: Competitive and execution risks remain: pre‑earnings coverage highlighted CRM competition and AI adoption challenges — key risks to watch in upcoming quarters as management executes on CRM and AI initiatives. Veeva Systems under pressure as earnings loom amid CRM competition

Veeva Systems Company Profile

(Get Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.